First post-surgical scarring therapeutic for glaucoma patients moves to Phase II study

Article

A Phase 2a clinical study has been initiated for Promedior's anti-fibrotic therapeutic, PRM-151, to evaluate its efficacy, safety and tolerability.

A Phase 2a clinical study has been initiated for Promedior’s anti-fibrotic therapeutic, PRM-151, to evaluate its efficacy, safety and tolerability. This drug is aimed at the prevention of post-surgical scarring in glaucoma patients. Currently, there are no approved drugs for this purpose or approved anti-fibrotic drug therapies in Europe or the US for any fibrotic disease.

PRM-151 is a recombinant form of a naturally circulating human protein, Pentraxin-2. This protein controls a basic process of the immune system and activates the body's natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation. A successful Phase 1 clinical study was completed at the beginning of 2010 and the drug has shown anti-fibrotic and anti-inflammatory activity in preclinical models.

Commenting on the initiation of Phase 2a clinical study Dominick Colangelo, president and CEO of Promedior, stated, “This study is designed to clearly demonstrate the anti-fibrotic activity of PRM-151 which we believe, based upon a common cellular immune mechanism across tissues and organs, may translate into potential therapeutic utility of PRM-151 in other ophthalmic surgical procedures…”

It is expected that 130 patients will be enrolled in the study who will receive the drug as a subconjunctival injection at the end of surgery and at additional designated times post-op. The primary efficacy endpoints will be improvement and maintenance of intraocular pressure and reduction in post-surgical scarring, which will be assessed by optical coherence tomography (OCT) and a clinical assessment scale.

This drug was granted Orphan Medicinal Product Designation by the European Commission in September 2009 for use in the prevention of scarring post glaucoma filtration surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.